Intrasense presence at ECR (European Congress of Radiology) from February 26 to March 2, 2025 in Vienna

- Enhancement of Liflow® 3.0[1]: presentation of DUOnco™ Bone 1.0[2], an AI-powered innovation in bone lesion detection
- Hosted two scientific presentations on AI innovation
- Presence on stand #223 (Hall X2)

Montpellier, France, February 3, 2025. Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, announces its participation in the European Congress of Radiology (ECR) 2025, which will take place between February 26 and March 2 in Vienna (Austria).

Alexandre Salvador, CEO of Intrasense, says: "*We are proud to once again participate in ECR, a key reference event for sharing our vision and innovations with the international radiology community. This edition is of particular importance, as we have the honor of previewing Liflow® 3.0 [1], integrating DUOnco™ Bone [2], a long-awaited breakthrough enabling radiologists to save even more time in exam analysis, automating complex tasks and optimizing their workflow. Intrasense's commitment is clear: to continue transforming the practice of oncology imaging, through innovative, intuitive and high-performance technological solutions, at the service of healthcare professionals and their patients.*"

The ECR, organized annually by the ESR (European Society of Radiology), is the largest radiology congress in Europe and the second largest in the world. Every year, it attracts over 20,000 participants, including more than 10,000 representatives from the medical community and over 8,000 from industry (imaging modalities, PACS, etc.). Radiology professionals from all over Europe and the world attend training courses, discover the latest innovations presented by exhibitors, and learn about research results during scientific presentations.

Innovative and unique solutions in oncology

Intrasense will present Liflow® 3.0 [1], the latest version of its oncology imaging platform enriched with AI algorithms, and a major innovation: DUOnco™ Bone 1.0[2], a new AI specifically dedicated to the analysis of bone lesions.
Highly anticipated by medical imaging professionals, this solution addresses a crucial challenge for radiologists in oncology follow-up. Assessing bone lesions is a complex, demanding and time-

---

[1] Version 3.0 under development, not CE marked

[2] Under development, not CE-marked, co-developed with Guerbet

consuming task marked by a significant risk of error: their detection has a probability of error two to three times higher than that of other anatomical regions. Developed in collaboration with Guerbet, DUOnco™ Bones 1.0 has been designed to transform this complexity into simplicity, accompanying radiologists in a faster and more accurate analysis of bone lesions.

Awarded the "Prix de l'Innovation" by the Société Française de Radiologie last October, Liflow® represents a major advance in oncology follow-up. Designed to facilitate and secure the analysis of CT-TAP scans using "multi-organ" artificial intelligence algorithms, the digital solution assists radiologists in optimizing patient care and treatment effectiveness. Developed in collaboration with the University Hospital of Angers and the Institut Gustave Roussy - Europe's leading cancer center and one of the world's top five cancer hospitals - Liflow® benefits from an ecosystem of excellence to accelerate its deployment. The project recently received €5.9 million in funding from France 2030, as part of a BPI France call for projects, testifying to its strategic relevance and potential impact on patient care.

The ECR will also highlight the Myrian® advanced radiology visualization platform, which continues to be enhanced by the integration of advanced, intelligent modules. Artificial intelligence-assisted detection and analysis functionalities, dedicated to lung and prostate analysis, reinforce its role as an essential solution to assist radiologists in interpreting complex examinations and ensuring accurate follow-up of pathologies.

A strategic collaboration with Guerbet

Once again this year, Intrasense will be exhibiting on Guerbet's booth, its key partner in the field of medical imaging. This cooperation reflects the continuation of a successful synergy between two actors committed to transforming cancer patients care with innovative oncology imaging solutions. Visitors will be able to discover the latest Intrasense and Guerbet innovative technologies and discuss their clinical applications with experts. In an AI dedicated area, within a "Home of Innovations" booth, the Intrasense team will be showcasing its AI- integrated solutions, designed to optimize healthcare professionals' workflows and improve diagnosis accuracy in oncology imaging.

Scientific recognition in the field of AI

Intrasense's R&D team, expert in the development of high added-value medical imaging solutions, will host two scientific presentations selected by the congress organization:

- March 1: Oral presentation at the "Artificial Intelligence in Thoracic Imaging" scientific session, on the influence of the number of lesions in evaluating the performance of AI algorithms to detect lung nodules.

- Electronic poster presentation on quick and efficient AI-based segmentation for high-resolution whole-body imaging. The focus will be on blood vessels and the work being done to improve the speed and performance of AI models.

These presentations will provide a unique opportunity for visibility and give attendees the opportunity to better understand the new challenges of AI in medical imaging and Intrasense's work in developing intelligent algorithms to assist radiologists in making faster and more accurate diagnosis.

About Intrasense

French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries to facilitate and secure diagnosis, decision-making and therapeutic follow-up.
Myrian®, an advanced visualization solution for radiology, provides 1,200 healthcare establishments with clinical applications to assist in the interpretation of all types of images. Since 2021, Intrasense has been developing Liflow®, a new multidisciplinary and collaborative platform dedicated to oncology, to optimize patient care and follow-up. A digital subsidiary of the Guerbet Group since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.
Further information at www.intrasense.fr

Contacts

INTRASENSE
Communications Officer
Salomé Sylvestre
Phone: +334 67 13 01 30
investisseurs@intrasense.fr

SEITOSEI.ACTIFIN
Analyst & Investor Relations
Foucauld Charavay
Phone: +336 37 83 33 19
intrasense@seitosei-actifin.com

Press Relations
Isabelle Dray
Phone: +331 56 88 11 29
isabelle.dray@seitosei-actifin.com